Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage.

Autor: Attia AA; Botany and Microbiology Department, Faculty of Science, Benha University, Benha, Egypt., Salama AF; Biochemistry Department, Faculty of Science, Tanta University, Tanta, Egypt., Eldiasty JG; Biology Department, University College of Haqel, University of Tabuk, Tabuk, Saudi Arabia., Mosallam SAE; Zoology Department, Women's College for Arts, Science and Education, Ain Shams University, Cairo, Egypt., El-Naggar SA; Physiology Department, Faculty of Science, Tanta University, Tanta, Egypt., El-Magd MA; Department of Anatomy, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt., Nasser HM; Biochemistry Department, Faculty of Science, Tanta University, Tanta, Egypt., Elmetwalli A; Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. dr.prof2011@gmail.com.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Apr 20; Vol. 12 (1), pp. 6494. Date of Electronic Publication: 2022 Apr 20.
DOI: 10.1038/s41598-022-10517-0
Abstrakt: The burden of cancer diseases is increasing every year, therefore, the demands to figure out novel drugs that can retain antitumor properties have been raised. This study aimed to investigate the anti-tumor properties of amygdalin (Amy) against Ehrlich ascites carcinoma (EAC) bearing mice and its protective properties against liver damage. Amy and the standard anticancer drug Sorafenib (Sor) were given alone or in combination to Swiss albino female mice that had been injected with EAC cells. Biochemical parameters of liver function (AST, ALT, GGT, total protein, albumin), tumor volume, oxidative stress [malondialdehyde, (MDA)] and antioxidative [superoxide dismutase (SOD), and reduced glutathione (GSH)] markers were measured. The hepatic expression of the antioxidant-related gene [nuclear factor erythroid-2-related factor 2 (Nrf2)], the migration-related gene [matrix metalloprotease 9 (MMP9)], and the angiogenesis-related gene [vascular endothelial growth factor (VEGF)] were evaluated by qPCR. The results revealed that EAC-bearing mice treated with Amy and/or Sor showed a decrease in the tumor burden and hepatic damage as evidenced by (1) decreased tumor volume, number of viable tumor cells; (2) increased number of dead tumor cells; (3) restored the liver function parameters; (4) reduced hepatic MDA levels; (5) enhanced hepatic GSH and SOD levels; (6) upregulated expression of Nrf2; (7) downregulated expression of MMP9 and VEGF, and (8) improved hepatic structure. Among all treatments, mice co-treated with Amy (orally) and Sor (intraperitoneally) showed the best effect. With these results, we concluded that the Amy improved the antitumor effect of Sor and had a protective role on liver damage induced by EAC in mice.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje